Health Care Distributors

Akso Health

Akso Health released FY2026 Q1 earnings on February 10 (EST), actual revenue USD 3.499 M, actual EPS USD -0.0015

Akso Health released FY2026 Semi-Annual Earnings on February 10, 2026 (EST) with actual revenue of USD 6.999 M and EPS of USD -0.003

Akso Health released FY2026 Q2 earnings on February 10 (EST), actual revenue USD 3.499 M, actual EPS USD -0.0015

Akso Health released FY2025 Q4 earnings on August 14, 2025 (EST) with actual revenue of USD 3.922 M and EPS of USD -0.202

Akso Health released FY2025 Annual Earnings on August 14 (EST), Actual Revenue: USD 14.78 M, Actual EPS: USD -0.48

Akso Health released FY2025 9 Months earnings on August 14 (EST), actual revenue USD 10.86 M, actual EPS USD -0.205

Akso Health released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 3.922M, actual EPS USD -0.202

Akso Health released FY2025 Q2 earnings on March 28 (EST), actual revenue USD 3.467 M, actual EPS USD -0.0012

Akso Health released FY2025 Semi-Annual Earnings on March 28 (EST), actual revenue USD 6.934 M, actual EPS USD -0.0025

Akso Health released FY2025 Q1 earnings on March 28 (EST), actual revenue USD 3.467 M, actual EPS USD -0.0012

Akso Health released FY2024 9 Months Earnings on July 30 (EST), with actual revenue of 1.654 M USD and EPS of -0.1993 USD

Akso Health released FY2024 Q2 earnings on January 3, 2024 (EST), with actual revenue of 446.79K USD and EPS of -0.0756 USD

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Akso Health Group has appointed CHI-LLTC as its new auditor, replacing Onestop Assurance PAC, effective May 12, 2026. This change reflects a shift in the company's governance and financial oversight priorities. Despite a history of losses and low revenue, the company is focusing on high-end medical technology. The auditor switch may impact investor sentiment amid ongoing financial uncertainties, with shares potentially trading at a premium. Investors are encouraged to conduct thorough research before making decisions.

Simplywall

SPDR S&P Health

iShares Global Healthcare

iShares US Healthcare Providers

iShares US Medical Devices

Health Care Select Sector SPDR

VG Health

SPDR S&P Health Equip

What Does Akso Health (AHG)'s Auditor Switch Reveal About Its Governance And Transparency Priorities?

Akso Health Group shares are trading higher after the company initiated an R&D program for its proprietary brain-computer interface technology.

benzinga_article

Akso Health Group (NASDAQ: AHG) has announced the initiation of a proprietary Brain-Computer Interface (BCI) R&D program aimed at developing transformative neurotechnology. The program will focus on innovations in neural sensing, AI neural decoding, and interface design, with patent applications pending. CEO Yilin Wang emphasized the strategic importance of this initiative for long-term growth in the global neurotechnology market. However, the company has not yet begun human clinical trials or generated revenue from BCI activities, and there are no guarantees of successful product development or regulatory approval.

StockTitan

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology | AHG Stock News

LABD

U.S. stock futures are down, with the Dow futures falling 400 points. Alto Neuroscience shares dropped 13.6% after disappointing Phase 2 trial results. Other stocks also fell in pre-market trading, including Akso Health Group (-9.4%), SharonAI Holdings (-8.8%), Progress Software (-8.3%), and Immunovant (-8.3%).

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Immunovant

Ark Genomic Revolution ETF

Alto Neuroscience

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SharonAI

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Progress Software

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

EBIZ

ONLN

IBUY

Akso Health Group (NASDAQ:AHG) shares fell 6% to $2.21, with trading volume increasing by 147% to 136,012 shares. Analysts maintain a consensus "Sell" rating, with Weiss Ratings reaffirming a "sell (d-)" rating. The stock's 50-day and 200-day moving averages are $1.69 and $1.61, respectively. Institutional ownership is at 1.21%, with SmartHarvest Portfolios LLC acquiring a new stake. Akso operates a social e-commerce platform in China, offering various products and services.

Market Beat

Global X E-commerce ETF

ProShares Online Retail

SPDR S&P Retail ETF

Amplify Online Retail ETF

Akso Health Group (NASDAQ:AHG)  Shares Down 6%   - Here's Why

Akso Health Group Sponsored ADR (NASDAQ:AHG) experienced a significant increase in short interest, rising 170.4% to 46,989 shares by March 13th. The short-interest ratio is currently 0.8 days based on an average trading volume of 56,241 shares. The stock is down 5.4%, with a current price of $2.27, and has a consensus rating of "Sell" from analysts. Institutional ownership stands at 1.21%.

Akso Health Group Sponsored ADR (NASDAQ:AHG) Sees Significant Growth in Short Interest

Shares of Akso Health Group (NASDAQ:AHG) experienced a significant trading volume increase of 377%, with 111,652 shares traded on Monday. The stock is currently priced at $2.46, down from a previous close of $2.50. Analysts have a "Sell" rating on the stock, with Weiss Ratings reaffirming a "sell (d-)" rating. Institutional ownership stands at 1.21%, with SmartHarvest Portfolios LLC acquiring a new stake. Akso Health Group operates a social e-commerce platform in China, offering various products and services.

Akso Health Group (NASDAQ:AHG) Sees Unusually-High Trading Volume  - Time to Buy?

Akso Health Group (AHG) shares surged 85.2% following a 75.6% revenue increase, reaching a new 52-week high. This growth raises questions about the company's sustainability amid past losses and cash concerns. Analysts suggest that while the revenue spike has attracted market attention, it does not resolve issues related to cash burn and reliance on new capital. Current fair value estimates for AHG stock hover around $0.25, indicating a complex investment narrative that requires careful consideration before making decisions.

Akso Health Group (AHG) Is Up 85.2% After 75.6% Revenue Surge And New 52-Week High - Has The Bull Case Changed?

Akso Health Group (NASDAQ:AHG) shares gapped down from $1.37 to $1.27 before trading on Tuesday, closing at $1.31 with a trading volume of 2,607 shares. Weiss Ratings has restated a "sell (d-)" rating for the stock, which currently holds an average rating of "Sell". Institutional investors own 1.21% of the stock, with SmartHarvest Portfolios LLC acquiring 16,748 shares recently. Akso Health Group operates a social e-commerce platform in China, offering various products and services. Analysts suggest considering other stocks over Akso Health Group.

Akso Health Group (NASDAQ:AHG) Shares Gap Down   - Time to Sell?

Akso Health(AHG.US)

What Does Akso Health (AHG)'s Auditor Switch Reveal About Its Governance And Transparency Priorities?

Akso Health Group shares are trading higher after the company initiated an R&D program for its proprietary brain-computer interface technology.

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology | AHG Stock News

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Akso Health Group (NASDAQ:AHG) Shares Down 6% - Here's Why

Akso Health Group Sponsored ADR (NASDAQ:AHG) Sees Significant Growth in Short Interest

Akso Health Group (NASDAQ:AHG) Sees Unusually-High Trading Volume - Time to Buy?

Akso Health Group (AHG) Is Up 85.2% After 75.6% Revenue Surge And New 52-Week High - Has The Bull Case Changed?

Akso Health Group (NASDAQ:AHG) Shares Gap Down - Time to Sell?